BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases
The development of mutant BRAF inhibitors has improved the outcome for melanoma patients with BRAFV600E mutations. Although the initial response to these inhibitors can be dramatic, sometimes resulting in complete tumor regression, the majority of melanomas become resistant. To study resistance to B...
Main Authors: | Florina Grigore, Hana Yang, Nicholas D. Hanson, Matthew W. VanBrocklin, Aaron L. Sarver, James P. Robinson |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-09-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558620301287 |
Similar Items
-
Histone 3 Methyltransferases Alter Melanoma Initiation and Progression Through Discrete Mechanisms
by: Sara E. DiNapoli, et al.
Published: (2022-02-01) -
Tackling malignant melanoma epigenetically: histone lysine methylation
by: Elias Orouji, et al.
Published: (2018-11-01) -
Braf protein mutation and its significancy within patients with melanoma
by: Julia Kuchnicka, et al.
Published: (2022-08-01) -
Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
by: Gulietta M. Pupo, et al.
Published: (2017-05-01) -
Current Advances in the Treatment of BRAF-Mutant Melanoma
by: Hima Patel, et al.
Published: (2020-02-01)